Hualan Biological Engineering Inc., a biopharmaceutical company, is engaged in the research, development, production, and commercialization of human blood products, viral vaccines, bacterial vaccines, and recombinant biologics in the People’s Republic of China. Its blood related products include human albumin; human immunoglobulin; human immunoglobulin for intravenous injection; human rabies immunoglobulin; human hepatitis B immunoglobulin; human tetanus immunoglobulin; human prothrombin complex; human coagulation factor VIII; human thrombin, lyophilized for external use; surgical lyophilized fibrin sealant; and human fibrinogen. The company’s vaccines comprise inactivated influenza vaccine; recombinant hepatitis B vaccine; meningococcal polysaccharide vaccine group ACYW135; and influenza A vaccine. It is also involved in the research and development, production, and distribution of genetic engineering products, protein chips, and other biological products, as well as bacterial, viral, and genetic engineering vaccines for human use. The company has a strategic alliance with the Chinese Academy of Sciences and collaborations with various institutes for the discovery of biologics. Hualan Biological Engineering Inc. was founded in 1992 and is based in Xinxiang, the People’s Republic of China.
hualan biological engineer-a
(002007:Shenzhen Stock Exchange)
Jia No. 1, Hualan Avenue
Phone: 86 37 3351 9992
|Beijing Tiantan Biological Products Corp Ltd||CNY38.29 CNY||+0.10|
|GlaxoSmithKline PLC||1,546 GBp||-38.50|
|Jiangxi Boya Bio-Pharmaceutical Co Ltd||CNY82.62 CNY||+0.81|
|Shanghai RAAS Blood Products Co Ltd||CNY55.79 CNY||-0.36|
|Sinovac Biotech Ltd||$4.96 USD||+0.01|
|View Industry Companies|
Sponsored Financial Commentaries
To contact HUALAN BIOLOGICAL ENGINEER-A, please visit www.hualanbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.